The Canadian entrepreneur has always pushed the boundaries of gene editing, once attempting to turn horses into unicorns. Now she is set on modifying human embryos – something her controversial ex-hus ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a ...

“MaxCyte reported $9.7 million of total revenue, including $6.2 million of core revenue and $3.4 million of SPL program-related revenue, which consists of milestones and royalties,” and CEO Maher ...

Hello, everyone. My name is Alec Stranahan. I cover CRISPR Therapeutics at Bank of America. Thanks for joining this session with CRISPR. And pleased to introduce Sam Kulkarni, the Chief Executive ...

With that as the backdrop, if you have $3,000 otherwise-idle bucks you're ready to put to work in the market, here's a closer look at three of your best bets right now. Roku's role within the ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter 2026 results were decent as it beat estimates for earnings and sales. The company’s total revenues of $2.99 billion rose 8% year over year, ...

Bullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead. The stock could soar if it delivers strong clinical progress over the next 12 months. Still, investors should ...